ArticleBreast cancer (Tokyo, Japan)2026
BRCA pathogenic variants and response in early TNBC patients treated with neoadjuvant pembrolizumab: outcomes of the BRCAPATH study.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent data on BRCA status and response to neoadjuvant pembrolizumab plus chemotherapy are limited. This study evaluated the association between BRCA status and pathological complete response (pCR) in patients with early triple-negative breast cancer (TNBC).
methodsBRCAPATH was a French multicenter retrospective study including 288 patients with early TNBC; 234 received neoadjuvant pembrolizumab plus chemotherapy and 54 received chemotherapy alone. pCR was defined as ypT0/TisN0 (TNM 8th edition). Associations between BRCA status and pCR were evaluated using Fisher's exact test and multivariable logistic regression. Survival was analyzed using the Kaplan-Meier method.
resultsIn the pembrolizumab-treated cohort, 35 patients (15.0%) carried BRCA pathogenic variants (PV) and pCR was achieved in 88.6% of BRCA PV carriers versus 52.1% of non-carriers (p < 0.001). In multivariable analysis, BRCA PV remained independently associated with pCR (OR 8.47, 95% CI 2.65-27.04; p < 0.001). In exploratory subgroup analyses, BRCA1 pathogenic variants remained significantly associated with pCR, whereas findings for BRCA2 were limited by the small number of carriers. No statistically significant survival difference was observed for BRCA PV carriers.
conclusionBRCA PV, particularly BRCA1, were strongly associated with pCR in pembrolizumab-treated early TNBC. These findings should be considered hypothesis-generating and warrant confirmation in larger prospective cohorts.
Indexed as
Identifiers
42301385What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.